Skip to main content

Taiwan Liposome Company, Ltd. (TLC)

NASDAQ: TLC · IEX Real-Time Price · USD
7.25 0.21 (2.97%)
Sep 17, 2021 4:00 PM EDT - Market closed
Market Cap311.67M
Revenue (ttm)3.63M
Net Income (ttm)-34.99M
Shares Out42.08M
EPS (ttm)-0.67
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume17,846
Open7.00
Previous Close7.04
Day's Range6.65 - 7.25
52-Week Range4.07 - 7.70
Beta0.80
AnalystsBuy
Price Target12.00 (+65.5%)
Est. Earnings DateOct 28, 2021

About TLC

Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). The BioSeizer lipid formulation technology is designed to enable local sustained release and fast onset of APIs at the site of disease or injury with enhanced pharmacokinetic (PK) control by customization of lipid layers; and NanoX active drug loading technology enables the pot...

IndustryBiotechnology
IPO DateNov 21, 2018
CEOJilong Hong
CountryTaiwan
Stock ExchangeNASDAQ
Ticker SymbolTLC
Full Company Profile

Financial Performance

In 2020, TLC's revenue was 101.93 million, a decrease of -51.26% compared to the previous year's 209.14 million. Losses were -983.31 million, 21.8% more than in 2019.

Financial numbers in millions TWDFinancial Statements

Analyst Forecast

According to 3 analysts, the average rating for TLC stock is "Buy." The 12-month stock price forecast is 12.00, which is an increase of 65.52% from the latest price.

Price Target
$12.00
(65.52% upside)
Analyst Consensus: Buy

News

TLC Announces Voluntary Delisting and Deregistration of American Depositary Shares

TAIPEI, Taiwan, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Taiwan Liposome Company or TLC (Nasdaq: TLC, TWO: 4152, “the Company”), a clinical-stage specialty pharmaceutical company developing novel nanomedicine...

1 week ago - GlobeNewsWire

TLC Reports Second Quarter 2021 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Aug. 12, 2021 (GLOBE NEWSWIRE) -- TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical n...

1 month ago - GlobeNewsWire

Short Squeeze Stocks: XELA, NEGG and 3 Other Stocks Experts Think Are Ready to Pop

Looking for the next AMC, retail investors are on the hunt for the next squeeze. Here are five short squeeze stocks to watch this week.

Other symbols:GMVDNEGGXELAMEDS
2 months ago - InvestorPlace

TLC Announces Details of Stock Swap Transactions

TAIPEI, Taiwan, July 05, 2021 (GLOBE NEWSWIRE) -- Taiwan Liposome Company (Nasdaq: TLC, TWO: 4152, “the company”), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to tar...

2 months ago - GlobeNewsWire

TLC and Zydus Enter Agreement to Launch AmphoTLC™ in India

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 26, 2021 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target ...

3 months ago - GlobeNewsWire

Taiwan Liposome Company, Ltd. Unsponsored ADR (TLC) Soars 30.3%: Is Further Upside Left in the Stock?

Taiwan Liposome Company, Ltd. Unsponsored ADR (TLC) saw its shares surge in the last session with trading volume being higher than average.

3 months ago - Zacks Investment Research

TLC Stock Jumps on India's Approval of Liposomal Amphotericin B As Black Fungus Treatment

India's Central Drugs Standard Control Organization has approved Taiwan Liposome Company's (NASDAQ: TLC) marketing application for Amphotericin B Liposome for 50mg Injection for immediate import to aid ...

3 months ago - Benzinga

TLC Announces Approval of New Drug Application of Liposomal Amphotericin B in India

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 25, 2021 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target ...

3 months ago - GlobeNewsWire

Why Scopus, NGM Biopharma and Taiwan Liposome Are Moving Today

Scopus BioPharma Inc. (NASDAQ: SCPS), NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) and Taiwan Liposome Company, Ltd. (NASDAQ: TLC) are among the biggest biopharma movers Monday.

Other symbols:NGMSCPS
3 months ago - Benzinga

Taiwan Liposome's Inhalable Liposome Formulations of Antiviral Drugs Show Promise In COVID-19

InspirMed Inc presented data on the potential advantages of inhalable liposome formulations of antiviral drugs at the International Society for Aerosols in Medicine Congress. InspirMed is a subsidiary o...

3 months ago - Benzinga

InspirMed Highlights Encouraging Data on ISPM21 and ISPM19 – Inhalable Liposome Formulations of Antiviral Drugs for C...

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 23, 2021 (GLOBE NEWSWIRE) -- InspirMed Inc., a subsidiary of TLC (Nasdaq: TLC, TWO: 4152) that specializes in the development of proprietary inhalable...

3 months ago - GlobeNewsWire

TLC Reports First Quarter 2021 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 14, 2021 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target ...

4 months ago - GlobeNewsWire

TLC Earns Highest Ranking in Corporate Governance Evaluation Seven Years Running

Praised as benchmark for small and medium-sized enterprises Praised as benchmark for small and medium-sized enterprises

4 months ago - GlobeNewsWire

InspirMed to Present at the 23rd International Society for Aerosols in Medicine (ISAM) Congress

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, April 26, 2021 (GLOBE NEWSWIRE) -- InspirMed Inc., a subsidiary of TLC (Nasdaq: TLC, TWO: 4152) that specializes in the development of inhalable liposome ...

4 months ago - GlobeNewsWire

TLC to Present at Upcoming Virtual Investor Conferences

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, March 02, 2021 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to targe...

6 months ago - GlobeNewsWire

TLC Reports Fiscal Year End 2020 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Feb. 05, 2021 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target...

7 months ago - GlobeNewsWire

TLC Announces Completion of US$15 Million Financing for Subsidiary InspirMed Inc.

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Jan. 04, 2021 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target...

8 months ago - GlobeNewsWire

TLC Announces Full Patient Enrollment in EXCELLENCE Trial of TLC599 for Osteoarthritis Pain

On-schedule completion of enrollment despite COVID-19 pandemic; unique trial design evaluates safety and efficacy of single & repeat doses On-schedule completion of enrollment despite COVID-19 pandemic;...

8 months ago - GlobeNewsWire

TLC Provides Corporate Update at Investor Conference

Patient enrollment of EXCELLENCE pivotal trial reaches 98%

9 months ago - GlobeNewsWire

TLC Announces Acceptance of Manuscript on Anti-COVID-19 Program by Clinical and Translational Science Journal

Technology can be quickly translated and applied to other drugs for direct, extended release delivery to the lungs and is open for collaboration Technology can be quickly translated and applied to other...

10 months ago - GlobeNewsWire

TLC Reports Third Quarter 2020 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 28, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target...

10 months ago - GlobeNewsWire

TLC Announces the Appointment of Thomas H. Bliss, Jr., MBA, as Chief Business Officer

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 21, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage, specialty pharmaceutical company developing novel nanomedicines to targe...

10 months ago - GlobeNewsWire

TLC Enrolls First Subject in Phase I Clinical Trial of Inhalable Anti-COVID-19 Program (TLC19)

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 14, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target...

11 months ago - GlobeNewsWire

TLC Receives Australian and Taiwan Approval to Initiate Phase I Clinical Trial of TLC19 Inhalable Liposomal Hydroxych...

Dual government support in streamlined development of anti-COVID-19 therapy Dual government support in streamlined development of anti-COVID-19 therapy

11 months ago - GlobeNewsWire

TLC to Present at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Sept. 21, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to tar...

11 months ago - GlobeNewsWire